deucravacitinib
bms
['#1117', ' psa', 'deucra']
deucravacitinib (tyk2 inihibitor) already studied in pso and psa, has show efficacy in a phase 2 trial for treatment of sle.
improvement in sri(4), bicla, llads, clasi-50 and joint count
abs#1117 #acr22 
Rheumatologist. Amateur chef. YNWA. Views and opinions are my own.